مجله دانشگاه علوم پزشکی سبزوار

شماره جاری

بر اساس شماره‌های نشریه

بر اساس نویسندگان

بر اساس موضوعات

نمایه نویسندگان

نمایه کلیدواژه ها

درباره نشریه

اهداف و چشم انداز

اعضای هیات تحریریه

اصول اخلاقی انتشار مقاله

بانک ها و نمایه نامه ها

پیوندهای مفید

فرایند پذیرش مقالات

اخبار و اعلانات

فرم های ضروری نشریه

راهنمای تنظیم مقاله

راهنمای نگارش خلاصه سیاستی

فرم خلاصه سیاستی

بررسی میزان بروز استئونکروز فک مرتبط با بیسفسفونات‌ها در بیماران شیمی‌درمانی در قم تا سال 1402

نوع مقاله : مقاله پژوهشی

نویسندگان

1 استادتمام، بخش جراحی دهان، فک و صورت، دانشکده دندانپزشکی، دانشگاه علوم پزشکی قم، قم، ایران

2 دندانپزشک، کمیته تحقیقات دانشجویی، دانشکده دندانپزشکی، دانشگاه علوم پزشکی قم، قم، ایران

3 دکتری بازیابی اطلاعات، پژوهشگر، مرکز تحقیقات سلامت معنوی، دانشگاه علوم پزشکی قم، قم، ایران

چکیده

زمینه و هدف: مصرف داروهایی نظری بیسفسفنات‌ها، ضد جذب‌ها و آنتی­آنژیوژنیک‌ها در طی روند درمانی بیماران تحت شیمی­درمانی، می‌تواند احتمال بروز برونژ را افزایش دهد. مطالعه حاضر باهدف تعیین درصد میزان بروز ضایعه در نواحی مختلف فک و در نظر داشتن مدت و نوع داروهای شیمی­درمانی مورداستفاده انجام شد.
مواد و روش­ها: در این مطالعه مقطعی پرونده ۷۴۹ بیمار که در طول 5 سال گذشته (1402-1397) در شهر قم به دلیل سرطان، دوره شیمی‌درمانی دریافت کرده بودند، بررسی شد. بیماران با میانگین سنی 85/13 ± 05/56 به شیوه تصادفی ساده و با در نظر گرفتن معیارهای ورود و متغیرهایی شامل نوع تشخیص سرطان، وجود یا عدم وجود متاستاز و.... انتخاب شدند. داده‌های استخراج‌شده با استفاده از نرم‌افزار آماری SPSS-22 تجزیه‌وتحلیل شد.
یافته­ها: بیشترین فراوانی بیماران مبتلا به انواع مختلف سرطان مربوط به پستان با 301 نفر و میانگین مدت درمان 46/0 ± 12/1 سال بود. بیشترین فراوانی از نظر داروی مصرفی در بیماران مربوط به آلندرونیت با 391 نفر بود. در 45 نفر از بیماران متاستاز وجود داشت. ارتباط معناداری بین بررسی ارتباط بروز برونژ با متغیرهای مختلف مشاهده نشد؛ اما در بررسی ارتباط بروز برونژ با شدت بیماری و محل ایجاد برونژ ارتباط معنادار مشاهده شد (001/0>P).
نتیجه‌گیری: باتوجه‌به نتایج مطالعه حاضر، میزان بروز برونژ در بیماران مورد­بررسی، میزان شدت برونژ و ناحیه آن می­تواند متفاوت باشد. بیشترین میزان بروز برونژ در ناحیه خلف فکین می­باشد و همچنین با افزایش مرحله بیماری میزان بروز آن کاهش پیدا می­کند.

تازه های تحقیق

https://scholar.google.com/citations?user=aIVfpXsAAAAJ&hl=en

https://pubmed.ncbi.nlm.nih.gov/?term=Mohammad+Mehdizadeh

https://scholar.google.com/citations?view_op=list_works&hl=en&user=Oz324bwAAAAJ

https://pubmed.ncbi.nlm.nih.gov/?term=mohammad+baghdadi

https://scholar.google.com/citations?hl=en&authuser=0&user=pYYa9NwAAAAJ

https://www.ncbi.nlm.nih.gov/myncbi/akram.mehrandasht.1/bibliography/public/

 

کلیدواژه‌ها

موضوعات

عنوان مقاله [English]

Study of the Incidence of Bisphosphonate-Related Osteonecrosis of the Jaw in Chemotherapy Patients in Qom, Iran until 2024

نویسندگان [English]

  • Mohammad Mehdizadeh 1
  • Akram Mehrandasht 2
  • Mohammad Baghdadi 3

1 Study of the Incidence of Bisphosphonate-Related Osteonecrosis of the Jaw in Chemotherapy Patients in Qom, Iran until 2024

2 Dentist of Students' Research Committee (SRC), Faculty of Dentistry, Qom University of Medical Sciences, Qom, Iran

3 PhD. Information Retrieval, Researcher of Spiritual Health Research Center, Qom University of Medical Sciences, Qom, Iran

چکیده [English]

Background: The use of bisphosphonates, anti-adsorption and anti-angiogenic drugs during the treatment process of chemotherapy patients can increase the likelihood of developing Bisphosphonate-Related Osteonecrosis of the Jaw. The present study was conducted to determine the percentage of lesion incidence in different areas of the jaw considering the duration and type of chemotherapy drugs used.
Materials and Methods: In this cross-sectional study, a total of 749 files of patients aged 18-92 years were coded and selected by simple random sampling, considering the inclusion criteria. Patients with a mean age of 56.05 ± 13.85 years were selected using simple random sampling, considering inclusion criteria and variables such as cancer diagnosis type, presence or absence of metastasis, etc. The extracted data were analyzed using SPSS version 22.
Results: The highest frequency of patients with different types of cancer was related to breast cancer with 301 patients and the average duration of treatment was 1.12 ± 0.46 years. The highest frequency in terms of drug use in patients was related to Alendronate with 391 patients; and 45 patients had metastases. No significant relationship was observed between the association of BRONJ incidence with different variables, but a significant association was observed between the BRONJ incidence, the severity of the disease and the location of BRONJ.
Conclusion: The incidence of BRONJ in the patients, the severity of bronzing and its area can vary. The highest incidence of BRONJ was in the posterior jaw area; and its incidence decreased with increasing disease grade.

کلیدواژه‌ها [English]

  • Dosimetry
  • Bisphosphonate-Associated
  • Osteonecrosis of the Jaw
  • Diphosphonates
  • Drug Therapy
  • Necrosis
مراجع
  1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. Journal of oral and maxillofacial surgery. 2014.56.1938(10)72. DOI: 10.1016/j.joms.2022.02.008.
  2. Migliorati CA, Saunders D, Conlon MS, Ingstad HK, Vaagen P, Palazzolo MJ, et al. Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction. The Journal of the American Dental Association. 2013;144(4):406-14. DOI: 10.14219/jada.archive.2013.0134.
  3. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104(1):83-93. https://doi.org/10.1002/cncr.21130.
  4. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. Journal of clinical periodontology. 2005;32(11):1123-8. DOI: 10.1111/j.1600-051X.2005.00842.x.
  5. Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19. DOI: 10.1016/j.bone.2011.04.022.
  6. Carmen Gabriela S, Bologa E, Boișteanu O, Lorina Platon A, Ovidiu Stelea S, Luminița Gelețu G, et al. "Bisphosphonate-Related Osteonecrosis of the Jaw: A 10-Year Analysis of Risk Factors and Clinical Outcomes. Journal of Clinical Medicine. 2025; 14, (13) 4445. https://doi.org/10.3390/jcm14134445.
  7. Spanou A, Lyritis G, Chronopoulos E, Tournis S. Management of bisphosphonate‐related osteonecrosis of the jaw: a literature review. Oral diseases. 2015;21(8):927-36. DOI: 10.1111/odi.12333.
  8. McClung MR. Bisphosphonates. Endocrinology and metabolism clinics of North America. 2003;32(1):253. DOI: 10.1016/S0889-8529(02)00079-8.
  9. De Rosa G, Misso G, Salzano G, Caraglia M. Bisphosphonates and cancer: what opportunities from nanotechnology? Journal of drug delivery. 2013;2013. https://doi.org/10.1155/2013/637976.
  10. Landesberg R, Eisig S, Fennoy I, Siris E. Alternative indications for bisphosphonate therapy. Journal of oral and maxillofacial surgery. 2009;67(5):27-34. DOI: 10.1016/j.joms.2008.12.006.
  11. Body J, Mancini Bisphosphonates for cancer patients: why, how, and when? Supportive care in cancer. 2002;10:399-407. DOI: 10.1007/s005200100292 .
  12. Drake MT, Clarke BL, Khosla S, editors. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clinic Proceedings; 2008: Elsevier. DOI: 10.4065/83.9.1032 .
  13. Diel I, Ansorge S, Hohmann D, Giannopoulou C, Niepel D, Intorcia M. Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany. Supportive Care in Cancer. 2020;28:5223-33. DOI: 10.1007/s00520-020-05357-5.
  14. Hernandez RK, Adhia A, Wade SW, O’Connor E, Arellano J, Francis K, et al. Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clinical epidemiology. 2015:335-45. DOI: 10.2147/CLEP.S85496.
  15. Shibahara T, Morikawa T, Yago K, Kishimoto H, Imai Y, Kurita K. National survey on bisphosphonate-related osteonecrosis of the jaws in Japan. Journal of oral and maxillofacial surgery. 2018;76(10):2105-12. DOI: 10.1016/j.joms.2018.04.009.
  16. Barasch A, Cunha-Cruz J, Curro F, Hujoel P, Sung A, Vena D, et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. Journal of dental research. 2011;90(4):439-44. DOI: 10.1177/0022034510397196.
  17. Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Archives of Medical Science. 2015;11(2):319-24. DOI: 10.5114/aoms.2015.50964.
  18. Kuroshima S, Sasaki M, Nakajima K, Tamaki S, Hayano H, Sawase T. Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. Bone. 2018;112:177-86.. DOI: 10.1016/j.bone.2018.05.001.
  19. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. Journal of Oral and Maxillofacial Surgery. 2009;67(5):35-43. DOI: 10.1016/j.joms.2009.01.003.
  20. Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA, Woo S-B. Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral oncology. 2013;49(9):977-83. https://doi.org/10.1016/j.oraloncology.2013.05.012.
  21. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on medication-related osteonecrosis of the jaw–2022 update. Journal of oral and maxillofacial surgery. 2022. DOI: 10.1016/j.joms.2022.02.008.
  22. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. American journal of otolaryngology. 2007;28(3):158-63 . DOI: 10.1016/j.amjoto.2006.08.004.
  23. Montebugnoli L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, Marchetti C. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2007;104(4):473-7. DOI: 10.1016/j.tripleo.2007.01.008.
  24. Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. International journal of oral and maxillofacial surgery. 2015;44(5):568-85. DOI: 10.1016/j.ijom.2015.01.026.
  25. Stübinger S, Dissmann JP, Pinho NC, Saldamli B, Seitz O, Sader R. A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er: YAG laser ablation. Lasers in Surgery and Medicine: The Official Journal of the American Society for Laser Medicine and Surgery. 2009;41(1):26-30. DOI: 10.1002/lsm.20730.
  26. Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca J-P, et al. Surgical approach with Er: YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers in medical science. 2010;25:101-13. DOI: 10.1002/lsm.20730.
  27. Goker F, Donati G, Grecchi F, Sparaco A, Ghezzi M, Rania V, et al. Treatment of BRONJ with ozone/oxygen therapy and debridement with piezoelectric surgery. European Review for Medical and Pharmacological Sciences .2020;24(17):9094-103. DOI: 10.26355/eurrev_202009_22855.
  28. Gul S, Dar J, Shah AA, Bashir S, Banoo N. Different treatment modalities of BRONJ: Our clinical experience. Journal of Advanced Medical and Dental Sciences Research. 2020;8(9):225-8. DOI: 10.21276/jamdsr.
  29. Marcianò A, Ingrasciotta Y, Isgrò V, L’Abbate L, Foti SS, Picone A, et al. Cancer patients at risk for medication-related osteonecrosis of the jaw. A case and control study analyzing predictors of MRONJ onset. Journal of Clinical Medicine. 2021;10(20):4762. DOI: 10.3390/jcm10204762.
  30. Ciobanu GA, Camen A, Ionescu M, Vlad D, Munteanu CM, Gheorghiță MI, et al. Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid. Journal of Clinical Medicine. 2023;12(11):3747. DOI: 10.3390/jcm12113747.
  31. Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, et al. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemotherapy and Pharmacology. 2021;87:871-7. Doi: 10.1007/s00280-021-04262-w.
  32. Hallmer F, Bjarnadottir O, Götrick B, Malmström P, Andersson G. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral surgery, oral medicine, oral pathology and oral radiology. 2020;130(3):252-7. DOI: 10.1007/s00784-021-04261-4.
  33. Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, et al. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study. Biol Pharm Bull. 2015;38(12):1850-5. doi: 10.1248/bpb.b15-00385. PMID: 26632176.
  34. Feng Z, An J, Zhang Y. Factors influencing severity of medication-related osteonecrosis of the jaw: a retrospective study. Journal of Oral and Maxillofacial Surgery. 2021;79(8):1683-8.. https://doi.org/10.1016/j.joms.2020.12.045.
  35. Petrovic M, Jelovac DB, Antic S, Antunovic M, Lukic N, Sabani M, et al. Medication-Related Osteonecrosis of the Jaws: Two Center Retrospective Cohort Studies. Biomed Res Int. 2019 Mar 18;2019:8345309. doi: 10.1155/2019/8345309. PMID: 31011580; PMCID: PMC6442486.
  36. Sahin,O. Medication-related osteonecrosis of the jaw: A survey of knowledge, practices and opinions of dentists. Ann Med Res 2020;27(9):2421-7. DOI: 10.5455/annalsmedres.2020.03.259.
مجله دانشگاه علوم پزشکی سبزوار
دوره 33، شماره 1
فروردین و اردیبهشت 1405
صفحه 757-767
فایل ها
سابقه مقاله
  • تاریخ دریافت: 27 اسفند 1403
  • تاریخ بازنگری: 08 مهر 1404
  • تاریخ پذیرش: 12 شهریور 1404
هم رسانی
ارجاع به این مقاله
آمار